Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Nandita Kachru, Holly M. Holmes, Michael L. Johnson, Hua Chen & Rajender R. Aparasu. (2021) Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Current Medical Research and Opinion 37:8, pages 1303-1313.
Read now
Read now
Gian Marco Rosa, Danilo Baccino, Alberto Valbusa, Carolina Scala, Fabio Barra, Claudio Brunelli & Simone Ferrero. (2018) Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. Expert Opinion on Drug Safety 17:5, pages 487-497.
Read now
Read now
Adrian Wagg, Victor W. Nitti, Con Kelleher, David Castro-Diaz, Emad Siddiqui & Todd Berner. (2016) Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Current Medical Research and Opinion 32:4, pages 621-638.
Read now
Read now
Umberto Leone Roberti Maggiore, Linda Cardozo, Simone Ferrero, Filomena Sileo, Alice Cola, Marco Torella, Nicola Colacurci, Massimo Candiani & Stefano Salvatore. (2014)
Mirabegron in the treatment of overactive bladder. Expert Opinion on Pharmacotherapy 15:6, pages 873-887.
Read now
Read now
Articles from other publishers (20)
Birkan İlhan, Tuğba Erdoğan, Eva Topinková & Gülistan Bahat. (2023) Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review. European Geriatric Medicine.
Crossref
Crossref
Zara Khizer, Muhammad R. Akram, Muhammad Azam Tahir, Weidong Liu, Shan Lou, Barbara R. Conway & Muhammad Usman Ghori. (2023) Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB). Pharmaceuticals 16:3, pages 372.
Crossref
Crossref
Michael A. Weber, Cornelia Haag-Molkenteller, Jennifer King, Ann Walker, Paul N. Mudd & William B. White. (2021) Effects of vibegron on ambulatory blood pressure in patients with overactive bladder. Blood Pressure Monitoring Publish Ahead of Print.
Crossref
Crossref
Jia-Pei Wu, Liao Peng, Xiao Zeng, Hao Li, Hong Shen & De-Yi Luo. (2020) Is imidafenacin an alternative to current antimuscarinic drugs for patients with overactive bladder syndrome?. International Urogynecology Journal 32:5, pages 1117-1127.
Crossref
Crossref
Nandita Kachru, Holly M. Holmes, Michael L. Johnson, Hua Chen & Rajender R. Aparasu. (2020) Risk of Mortality Associated with Non-selective Antimuscarinic medications in Older Adults with Dementia: a Retrospective Study. Journal of General Internal Medicine 35:7, pages 2084-2093.
Crossref
Crossref
William B. White, Emad Siddiqui, Tri Tat, Billy Franks & Carol R. Schermer. (2018) Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. Journal of the American Society of Hypertension 12:11, pages 768-778.e1.
Crossref
Crossref
William B. White, Christopher Chapple, Christian Gratzke, Sender Herschorn, Dudley Robinson, Jeffrey Frankel, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, Robert van Maanen & Michael A. Weber. (2018)
Cardiovascular Safety of the β
3
-Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial
. The Journal of Clinical Pharmacology 58:8, pages 1084-1091.
Crossref
Crossref
Youn-Jung Son & Bo Eun Kwon. (2018) Overactive Bladder is a Distress Symptom in Heart Failure. International Neurourology Journal 22:2, pages 77-82.
Crossref
Crossref
Michael A. Weber, Christopher R. Chapple, Christian Gratzke, Sender Herschorn, Dudley Robinson, Jeffrey M. Frankel, Arwin M. Ridder, Matthias Stoelzel, Asha Paireddy, Robert van Maanen & William B. White. (2018) A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects. Blood Pressure Monitoring 23:3, pages 153-163.
Crossref
Crossref
C. Chesnel, A. Charlanes, C. Hentzen, N. Turmel, X. Biardeau, C. Brochard, S. Campagne, G. Capon, X. Deffieux, B. Fatton, X. Gamé, R. Haddad, C. Jeandel, J. Kerdraon, P. Manceau, P. Mares, M. Mezzadri, P. Mongiat-Artus, A.-C. Petit, B. Peyronnet, J.-M. Soler, C. Thuillier, J.-M. Vetel, G. Robain & G. Amarenco. (2018) Effets cardio-vasculaires des traitements anticholinergiques à visée vésicale chez la personne âgée : une revue. Progrès en Urologie 28:7, pages 361-369.
Crossref
Crossref
Alejandro Arana, Andrea V. Margulis, Lisa J. McQuay, Ryan Ziemiecki, Jennifer L. Bartsch, Kenneth J. Rothman, Billy Franks, Milbhor D'Silva, Kwame Appenteng, Cristina Varas-Lorenzo & Susana Perez-Gutthann. (2018) Variation in Cardiovascular Risk Related to Individual Antimuscarinic Drugs Used to Treat Overactive Bladder: A UK Cohort Study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:6, pages 628-637.
Crossref
Crossref
Andrea V. Margulis, Jesper Hallas, Anton Pottegård, Nina Sahlertz Kristiansen, Willem Jan Atsma, Billy Franks, Milbhor D’Silva, Cristina Varas-Lorenzo, Susana Perez-Gutthann & Alejandro Arana. (2017) Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study. European Journal of Clinical Pharmacology 74:2, pages 193-199.
Crossref
Crossref
David Staskin, Sender Herschorn, Jonathan Fialkov, Le Mai Tu, Terry Walsh & Carol R. Schermer. (2017) A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). International Urogynecology Journal 29:2, pages 273-283.
Crossref
Crossref
William Gibson, Scott MacDiarmid, Moses Huang, Emad Siddiqui, Matthias Stölzel, Nurul Choudhury & Marcus J. Drake. (2017) Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. European Urology Focus 3:6, pages 629-638.
Crossref
Crossref
Marcus J. Drake, Scott MacDiarmid, Christopher R. Chapple, Adil Esen, Stavros Athanasiou, Javier Cambronero Santos, David Mitcheson, Sender Herschorn, Emad Siddiqui, Moses Huang & Matthias Stoelzel. (2017) Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). International Journal of Clinical Practice 71:5, pages e12944.
Crossref
Crossref
Gian Marco Rosa, Simone Ferrero, Victor W. Nitti, Adrian Wagg, Tahir Saleem & Christopher R. Chapple. (2016) Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. European Urology 69:2, pages 311-323.
Crossref
Crossref
Matteo Bauckneht, Gianmario Sambuceti, Elena Pomposelli, Francesco Fiz & Cecilia Marini. (2015) Pathophysiological basis of myocardial innervation imaging in heart failure. Clinical and Translational Imaging 3:5, pages 347-355.
Crossref
Crossref
Karl-Erik Andersson. (2015) Drug therapy of overactive bladder - What is coming next?. Korean Journal of Urology 56:10, pages 673.
Crossref
Crossref
Karl-Erik Andersson. 2014. Bladder Dysfunction in the Adult. Bladder Dysfunction in the Adult
121
222
.
Bülent ÇetinelBulent Onal. (2013) Rationale for the Use of Anticholinergic Agents in Overactive Bladder With Regard to Central Nervous System and Cardiovascular System Side Effects. Korean Journal of Urology 54:12, pages 806.
Crossref
Crossref